European association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update

Morgan Rouprêt, Marko Babjuk, Eva Compérat, Richard Zigeuner, Richard J. Sylvester, Maximilian Burger, Nigel C. Cowan, Andreas Böhle, Bas W.G. Van Rhijn, Eero Kaasinen, Joan Palou, Shahrokh F. Shariat

Research output: Contribution to journalArticleResearchpeer-review

432 Citations (Scopus)


© 2015 European Association of Urology. Context The European Association of Urology (EAU) guidelines panel on upper urinary tract urothelial cell carcinoma (UTUC) has prepared updated guidelines to aid clinicians in the current evidence-based management of UTUC and to incorporate recommendations into clinical practice. Objective To provide a brief overview of the EAU guidelines on UTUC as an aid to clinicians. Evidence acquisition The recommendations provided in the current guidelines are based on a thorough review of available UTUC guidelines and articles identified following a systematic search of Medline. Data on urothelial malignancies and UTUC were searched using these keywords: urinary tract cancer; urothelial carcinomas; upper urinary tract, carcinoma; renal pelvis; ureter; bladder cancer; chemotherapy; nephroureterectomy; adjuvant treatment; instillation; neoadjuvant treatment; recurrence; risk factors; and survival. References were weighted by a panel of experts. Evidence synthesis Due to the rarity of UTUC, there are insufficient data to provide strong recommendations (ie, grade A). However, the results of recent multicentre studies are now available, and there is a growing interest in UTUC. The 2009 TNM classification is recommended. Recommendations are given for diagnosis and risk stratification as well as radical and conservative treatment, and prognostic factors are discussed. A single postoperative dose of intravesical mitomycin after nephroureterectomy reduces the risk of bladder tumour recurrence. Recommendations are also provided for patient follow-up after different therapeutic strategies. Conclusions These guidelines contain information on the management of individual patients according to a current standardised approach. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen, based on the proposed risk stratification of these tumours. Patient summary Urothelial carcinoma of the upper urinary tract is rare, but because 60% of these tumours are invasive at diagnosis, an appropriate diagnosis is most important. A number of known risk factors exist.
Original languageEnglish
Pages (from-to)868-879
JournalEuropean Urology
Issue number5
Publication statusPublished - 1 Nov 2015


  • Cytology
  • Guidelines
  • Nephroureterectomy
  • Renal pelvis
  • Risk factors
  • Survival
  • Ureter
  • Ureteroscopy
  • Urinary tract cancer
  • Urothelial carcinoma


Dive into the research topics of 'European association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update'. Together they form a unique fingerprint.

Cite this